{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:56:20Z","timestamp":1781157380584,"version":"3.54.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006694","name":"Associazione Italiana Contro le Leucemie - Linfomi e Mieloma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116790","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:26:31Z","timestamp":1778757991000},"page":"116790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Burden and management of infectious diseases in patients treated by chimeric antigen-receptor T (CAR-T)-cell therapy for refractory or relapsing diffuse large B-cell lymphoma or multiple myeloma"],"prefix":"10.1016","volume":"242","author":[{"given":"Mariantonietta","family":"Pisaturo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierantonio","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Onorato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Frigeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4949","authenticated-orcid":false,"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib1","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116790_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/CMAR.S400013","article-title":"Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancer Manag Res"},{"issue":"14","key":"10.1016\/j.ejca.2026.116790_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116790_bib5","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116790_bib6","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"S1","key":"10.1016\/j.ejca.2026.116790_bib7","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116790_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018893","article-title":"5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"10254","key":"10.1016\/j.ejca.2026.116790_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ejca.2026.116790_bib11","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2026.116790_bib12","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell\u2013recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch De Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2026.116790_bib13","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10297","key":"10.1016\/j.ejca.2026.116790_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2026.116790_bib15","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib17","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/cancers13071684","article-title":"Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.ejca.2026.116790_bib18","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116790_bib20","article-title":"Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells","volume":"4","author":"Strati","year":"2023","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17474086.2022.2063833","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified t cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"18","key":"10.1016\/j.ejca.2026.116790_bib23","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.116790_bib24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116790_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2026.116790_bib27","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen\u2013directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ejca.2026.116790_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/CAD.0000000000001485","article-title":"Therapeutic efficacy and infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy","volume":"34","author":"Gao","year":"2023","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib31","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Jennifer","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib32","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00277-023-05131-7","article-title":"Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature","volume":"102","author":"Mercadal","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib33","article-title":"High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma","volume":"8","author":"O\u2019Reilly","year":"2024","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116790_bib35","article-title":"Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy [Internet]","author":"Pout\u00f3n","year":"2023","journal-title":"Review"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib36","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","volume":"62","author":"Wittmann Dayagi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"S1","key":"10.1016\/j.ejca.2026.116790_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14191","article-title":"Infectious complications among CD19 CAR-T cell therapy recipients: a single-center experience","volume":"25","author":"Walker","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/imr.12823","article-title":"T-cell exhaustion in HIV infection","volume":"292","author":"Fenwick","year":"2019","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.ejca.2026.116790_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116790_bib40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2026.116790_bib41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.ejca.2026.116790_bib42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib43","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Thiruvengadam","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib44","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.ejca.2026.116790_bib45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ccell.2022.01.010","article-title":"Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients","volume":"40","author":"Sesques","year":"2022","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ejca.2026.116790_bib46","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.ejca.2026.116790_bib47","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/cancers15184671","article-title":"Outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL): a single-institution experience","volume":"15","author":"Trando","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ejca.2026.116790_bib48","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib49","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116790_bib50","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"32","key":"10.1016\/j.ejca.2026.116790_bib51","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116790_bib52","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2026.116790_bib53","unstructured":"ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions [Internet]. Available from: \u3008https:\/\/www.hematology.org\/covid-19\/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients\u3009."},{"issue":"2","key":"10.1016\/j.ejca.2026.116790_bib54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"S1","key":"10.1016\/j.ejca.2026.116790_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"10.1016\/j.ejca.2026.116790_bib56","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.ejca.2026.116790_bib57","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116790_bib58","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jaci.2024.10.021","article-title":"Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality","volume":"155","author":"Sutherland","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116790_bib59","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.ejca.2026.116790_bib60","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"issue":"12","key":"10.1016\/j.ejca.2026.116790_bib62","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1093\/jac\/dkae360","article-title":"Impact of discontinuing routine fluoroquinolone prophylaxis in neutropenic allogeneic haematopoietic stem cell transplant recipients: an observational study","volume":"79","author":"Stern","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.ejca.2026.116790_bib63","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib64","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"2","key":"10.1016\/j.ejca.2026.116790_bib65","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.ejca.2026.116790_bib66","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.ejca.2026.116790_bib68","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib70","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjh.18690","article-title":"Outcome of early treatment of SARS-CoV -2 infection in patients with haematological disorders","volume":"201","author":"Mikulska","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116790_bib71","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"26","key":"10.1016\/j.ejca.2026.116790_bib72","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2141.2001.02882.x","article-title":"Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia","volume":"114","author":"Sinisalo","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib75","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.ejca.2026.116790_bib76","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient","volume":"223","author":"Baang","year":"2021","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.ejca.2026.116790_bib78","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116790_bib79","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ejca.2026.116790_bib80","doi-asserted-by":"crossref","first-page":"E815","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study","volume":"73","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7853","key":"10.1016\/j.ejca.2026.116790_bib81","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp SA","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejca.2026.116790_bib82","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/infdis\/jiab075","article-title":"Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection","volume":"223","author":"Tarhini","year":"2021","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.ejca.2026.116790_bib83","first-page":"788","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy\u2014a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"10.1016\/j.ejca.2026.116790_bib84","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/bloodadvances.2022009578","article-title":"Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post\u2013CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey","volume":"7","author":"van Doesum","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.ejca.2026.116790_bib85","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ccell.2022.06.012","article-title":"Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer","volume":"40","author":"Ehmsen","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2022.02.011","article-title":"Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination","volume":"40","author":"Ehmsen","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116790_bib87","unstructured":"SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population [Internet]; 2025 [cited 2025 Dec 22]. Available from: \u3008https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/supernova-trial-met-covid-19-prevention-endpoint.html?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.ejca.2026.116790_bib88","unstructured":"ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants [Internet]. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/other\/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2-variants-december-2024-update_en.pdf\u3009."},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib89","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40121-023-00789-y","article-title":"Consistent effects of early remdesivir on symptoms and disease progression across at-risk outpatient subgroups: treatment effect heterogeneity in PINETREE study","volume":"12","author":"Brown","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib90","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2026.116790_bib91","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ejca.2026.116790_bib92","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with covid-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116790_bib93","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.116790_bib94","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/cid\/ciab695","article-title":"Remdesivir for the prevention of invasive mechanical ventilation or death in coronavirus disease 2019 (COVID-19): a post hoc analysis of the adaptive COVID-19 treatment trial-1 cohort data","volume":"74","author":"Paules","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.ejca.2026.116790_bib95","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S1473-3099(22)00430-3","article-title":"Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection","volume":"22","author":"Sun","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.ejca.2026.116790_bib96","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3390\/v15051199","article-title":"Efficacy of remdesivir and neutralizing monoclonal antibodies in monotherapy or combination therapy in reducing the risk of disease progression in elderly or immunocompromised hosts hospitalized for COVID-19: a single center retrospective study","volume":"15","author":"Bavaro","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.ejca.2026.116790_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad189","article-title":"Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir\/ritonavir: case series","volume":"10","author":"Breeden","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.ejca.2026.116790_bib98","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/cid\/ciac868","article-title":"Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir","volume":"76","author":"Ford","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ejca.2026.116790_bib99","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ejca.2026.116790_bib100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/QCO.0000000000001070","article-title":"Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients","volume":"37","author":"Sepulcri","year":"2024","journal-title":"Curr Opin Infect Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600571X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600571X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:56:26Z","timestamp":1781153786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600571X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":100,"alternative-id":["S095980492600571X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116790","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden and management of infectious diseases in patients treated by chimeric antigen-receptor T (CAR-T)-cell therapy for refractory or relapsing diffuse large B-cell lymphoma or multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116790"}}